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A shear-dependent NO-cGMP-cGKI cascade
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of thrombosis
Lai Wen 1,5, Susanne Feil1, Markus Wolters1, Martin Thunemann 1, Frank Regler1, Kjestine Schmidt2,
Andreas Friebe3, Marcus Olbrich4, Harald Langer4, Meinrad Gawaz 4, Cor de Wit 2 & Robert Feil1
Mechanisms that limit thrombosis are poorly defined. One of the few known endogenous
platelet inhibitors is nitric oxide (NO). NO activates NO sensitive guanylyl cyclase (NO-GC)
in platelets, resulting in an increase of cyclic guanosine monophosphate (cGMP). Here we
show, using cGMP sensor mice to study spatiotemporal dynamics of platelet cGMP, that
NO-induced cGMP production in pre-activated platelets is strongly shear-dependent. We
delineate a new mode of platelet-inhibitory mechanotransduction via shear-activated NO-GC
followed by cGMP synthesis, activation of cGMP-dependent protein kinase I (cGKI), and
suppression of Ca2+ signaling. Correlative profiling of cGMP dynamics and thrombus for-
mation in vivo indicates that high cGMP concentrations in shear-exposed platelets at the
thrombus periphery limit thrombosis, primarily through facilitation of thrombus dissolution.
We propose that an increase in shear stress during thrombus growth activates the
NO-cGMP-cGKI pathway, which acts as an auto-regulatory brake to prevent vessel occlusion,
while preserving wound closure under low shear.
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P latelets are key players in hemostasis and thrombosis aftervascular injury. Drugs that inhibit platelet activation andaggregation are commonly used in the management of
acute coronary syndromes, but can also cause life-threatening
bleeding. An optimal hemostatic response is defined as one suf-
ficient to stop bleeding without unwarranted vascular thrombotic
occlusion1–4. The importance of local hemodynamic conditions
for platelet accumulation at sites of injury is well known and
the molecular players that promote platelet activation and
thrombus formation under high flow/shear have been studied in
great detail5,6. In contrast, mechanisms that suppress thrombosis
are less well understood. One of the few known endogenous
platelet inhibitors is nitric oxide (NO). It is generally accepted
that NO is supplied by the endothelium and then binds to and
activates NO-sensitive guanylyl cyclase (NO-GC) in platelets,
resulting in an increase of intraplatelet cyclic guanosine mono-
phosphate (cGMP)7,8.
Although genetic studies have demonstrated the importance of
NO-cGMP signaling in cardiovascular health and disease in
humans9,10, the underlying cellular and molecular mechanisms
are not completely understood. It is long known that platelets
express high levels of NO-GC and cGMP-dependent protein
kinase I (cGKI), and that the intraplatelet cGMP concentration
can be increased in vitro by incubation with NO, or with drugs
that stimulate NO-GC or inhibit cGMP degradation by phos-
phodiesterases (PDEs)11–13. However, the (patho-)physiological
and therapeutic relevance of platelet cGMP signaling for
hemostasis and thrombosis is not clear14–16. While it is well
established that the NO-cGMP pathway is a major mechanism
for platelet inhibition, it is increasingly recognized that this
pathway may in fact play a biphasic role in both platelet activa-
tion and inhibition. An increase in platelet cGMP has been linked
to platelet activation induced by several receptor signaling path-
ways, including recently discovered platelet pattern-recognition
receptor signaling pathways that are triggered by damage-
associated molecular pattern molecules such as high mobility
group box 1 protein17.
The uncertainty as to the function of cGMP in platelets is in
part related to the fact that it was not possible to monitor
dynamic changes of the cGMP concentration in living platelets.
Furthermore, many experiments have been performed with iso-
lated platelets in vitro under conditions that do not completely
represent the in vivo situation with regard to platelet interactions
with immobilized substrates, other cell types, blood flow, and
shear forces that affect platelet activity under in vivo condi-
tions18–20. In particular, the potential influence of shear stress on
the activity of the cGMP cascade in platelets has not been con-
sidered until now. To study the role of flow/shear stress for NO-
cGMP signaling in platelets, we have generated cGMP sensor
mice that enable real-time visualization of cGMP signals during
thrombus formation. We find that NO-induced cGMP produc-
tion in pre-activated platelets is strongly shear-dependent both in
a flow chamber assay as well as in two mouse models of arterial
injury and thrombosis. The mechanosensitive NO-cGMP-cGKI
pathway identified in this study acts as an auto-regulatory brake
to prevent vessel occlusion under high shear, while preserving
wound closure under low shear.
Results
Visualization of cGMP signals in platelets under flow. We first
examined the effect of NO on thrombus formation on a collagen-
coated surface ex vivo using a flow chamber system. In the pre-
sence of the NO-donor DEA/NO (1 µM), murine platelets formed
significantly smaller thrombi than untreated controls (Fig. 1a).
Inhibition of thrombus formation by DEA/NO was strongly
attenuated when blood from SM-Iβ rescue mice21 lacking cGKI in
platelets was used, demonstrating an anti-thrombotic action of
the NO-cGMP-cGKI cascade under flow in vitro. A similar anti-
thrombotic effect of DEA/NO was observed in human platelets
under flow (Supplementary Fig. 1). The residual weak, but sta-
tistically significant (P= 0.04, Student’s t-test), inhibition of
cGKI-deficient thrombi by DEA/NO (Fig. 1a) indicated a minor
cGMP-cGKI independent anti-thrombotic activity of NO.
To visualize cGMP signals in real time in living platelets under
flow and to correlate the spatiotemporal cGMP profile with
platelet behavior, we used transgenic cGMP sensor mice22 that
express a fluorescence resonance energy transfer (FRET)- based
cGMP sensor, cGi500, in platelets. In these mice, a Cre-activatable
loxP-modified cGi500 construct is integrated into the Rosa26
locus and driven by the CAG promoter. In the present study, we
used mice with either ubiquitous sensor expression (cGi500-L1
mice) or Pf4-Cre-activated23 sensor expression specifically in
megakaryocytes/platelets (cGi500-L2fl/fl; Pf4-Cretg/+ mice) (Sup-
plementary Fig. 2a). The cGi500 sensor contains a cGMP-binding
domain flanked by CFP and YFP. Upon excitation of CFP, part
of the emitted energy is transferred via FRET to YFP, which is
then also excited. When cGMP binds to the sensor, its FRET
efficiency is decreased. Thus, the ratio of CFP over YFP emission
(F480/F535) indicates the intracellular cGMP concentration
(Supplementary Fig. 2b).
Initially, we have established cGMP imaging in cGi500-
expressing platelets adhered to collagen in a flow chamber
(Supplementary Fig. 3a). Indeed, strong YFP fluorescence was
observed in aggregated thrombi as well as single platelets
(Supplementary Fig. 3b and Supplementary Fig. 5a, b). Note that
YFP fluorescence indicates the expression level of cGi500, but not
the intracellular cGMP concentration. The thrombi in the flow
chamber stained positive for the platelet activation marker
P-selectin (Supplementary Fig. 3c) confirming that the platelets
were indeed activated24. To validate the system for cGMP
imaging, thrombi were continuously superfused with buffer in the
absence and presence of test compounds. While application of
CNP and ANP (ligands of guanylyl cyclases not known to be
expressed in platelets) did not evoke any FRET/cGMP changes,
superfusion with DEA/NO triggered fast, robust, reversible, and
concentration-dependent FRET changes reflecting an increase in
cGMP in platelet thrombi under flow (Supplementary Fig. 3d, e).
Pre-incubation with pharmacological inhibitors of PDE2 (BAY
60-7550), PDE3 (milrinone), or PDE5 (tadalafil) potentiated
NO-induced cGMP transients demonstrating that these PDEs
degrade cGMP in platelets (Supplementary Fig. 3f–h). These data
are in line with previous studies of cGMP signaling in
platelets12,13.
NO-cGMP signaling in pre-activated platelets is shear-
dependent. Surprisingly, flow chamber experiments in which
we switched the superfusion off and on revealed that NO-
triggered cGMP signals in platelet thrombi are dependent on fluid
shear stress. As shown in Fig. 1b and Supplementary Movie 1,
application of 100 nM DEA/NO at a shear rate of 500 s−1 led to
sustained cGMP elevation, but switching off the fluid flow led to a
rapid decrease of the intracellular cGMP concentration to the
basal level within ~20 s, although DEA/NO was still present. In
the presence of DEA/NO, repeated initiation and cessation of
flow (flow on/off) led to repeated cGMP increases and decreases,
respectively. Based on a calibration scale of the cGi500 sensor
(Fig. 1b, upper right)25, the flow-induced cGMP elevations were
robust, reaching a concentration of ≥3 µM cGMP (Fig. 1b). Note
that the apparent plateau of the cGMP signal (ratio R, black trace)
was most likely due to sensor saturation above 3 µM cGMP25.
The possibility that the flow-dependent FRET/cGMP changes
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were artifacts was excluded by several control experiments.
First, the individual emission intensities for CFP (cyan) and
YFP (yellow) changed into opposite directions indicating that a
proper FRET change was observed with our ratiometric sensor
rather than quenching or fluorescence artifacts (Fig. 1b). Second,
the flow-dependent FRET/cGMP signals correlated well with
phosphorylation of vasodilator-stimulated phosphoprotein
(VASP) (Fig. 1c), a well-known substrate of cGMP-activated
cGKI in platelets13. Third, the magnitude of the cGMP signals
could be titrated by increasing shear rates (Fig. 1d). Fourth,
application of flow alone in the absence of NO did not evoke
cGMP signals (Fig. 1e, left). Fifth, flow-induced cGMP signals
in the presence of NO were almost absent in cGi500-expressing
platelets with a conditional NO-GC knockout (Fig. 1f). The
corresponding mice were obtained by crossing platelet-specific
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the NO-GC β1 subunit26 resulting in mice with platelet-
specific cGi500 expression and platelet-specific NO-GC deletion
(cGi500-L2fl/fl; Pf4-Cretg/+; NO-GC β1fl/fl). Although the effi-
ciency of Pf4-Cre driven knockouts is very high in platelets23, we
cannot exclude a low level of residual NO-GC expression in some
platelets of our conditional NO-GC knockout mice. This might
also explain the weak FRET changes triggered by flow and NO in
thrombi derived from these mice (Fig. 1f). We observed flow-
sensitive cGMP responses also in the presence of higher con-
centrations of DEA/NO (250 nM, 500 nM) (Supplementary
Fig. 4). As expected27, stimulation with high concentrations of
DEA/NO, in particular with 500 nM, induced fast desensitization
of the mechanosensitive cGMP response.
Since the results described above were obtained with
preformed thrombi consisting of hundreds of aggregated
platelets, we tested how individual platelets would respond to
shear stress and NO. Indeed, NO-dependent cGMP increases in
single adherent platelets were also highly sensitive to flow,
both on a collagen- and fibrinogen-coated surface (Supplemen-
tary Fig. 5a, b). We further tested the effect of mechanical stress
on NO-induced cGMP responses in platelets in suspension.
Because our FRET imaging setup is not suitable for cGMP
imaging in floating cells, we measured cGMP by a conventional
immunoassay. Platelet suspensions were exposed to DEA/NO
(50 nM) under static conditions or during mild shaking.
Although the shear stress generated under our shaking
conditions was not well defined, we detected in these platelets
a higher cGMP level than in platelets kept under static
conditions (Supplementary Fig. 5c). However, the NO/shear-
induced cGMP increase in floating platelets appeared to be
weaker than in adherent platelets in a flow chamber. Taken
together, our results indicated that shear stress potentiates
NO-cGMP signaling in platelets. This mechanosensory system
is apparently more efficient in adherent versus floating platelets,
but does not require platelet-platelet interactions present in
thrombi nor interactions of platelets with specific immobilized
substrates.
NO-GC activity is regulated by fluid shear stress. Next, we
investigated which component(s) of the cGMP pathway is/are
regulated by fluid shear stress. The intracellular cGMP con-
centration in platelets depends on the rates of cGMP synthesis via
NO-GC, cGMP degradation via PDEs, and cGMP efflux via
cGMP transporters. Thus, the cGMP increase elicited by flow in
the presence of NO could be caused by sensitization of NO-GC
for NO, inactivation of PDEs and/or inhibition of cGMP
efflux. Application of the NO-GC inhibitor ODQ to thrombi
in the presence of flow and DEA/NO led to a fast decrease of
the intracellular cGMP concentration to basal levels (Fig. 2a,
right). If PDEs were the shear stress-sensitive components,
then one would expect that their activity is relatively low
under flow and consequently, the fall of cGMP in the presence of
NO, ODQ and flow should also be slow. However, we observed a
rapid cGMP decrease after acute NO-GC inhibition with ODQ in
the presence of flow, with kinetics similar to the decrease of
cGMP after flow cessation in the absence of ODQ (Fig. 2a). These
data indicated that shear stress increases NO sensitivity of
NO-GC rather than decreases cGMP degradation by PDEs.
Similar results were obtained with two alternative NO-donors,
SPER/NO and DETA/NO, in the presence and absence of flow
and ODQ (Fig. 2b, c). Flow-dependent cGMP signals were also
observed in the presence of BAY 41-2272 (Fig. 2d) and riociguat
(Fig. 2e), so-called NO-GC stimulators that are able to activate
NO-GC in the absence of NO28. Compared to flow-regulated
cGMP transients in the presence of NO, these cGMP signals
showed slower off-rates. The relatively slow decline of the cGMP
signal after cessation of flow in the presence of BAY 41-2272
might at least in part be due to the fact that this compound also
inhibits PDE529. Interestingly, cGMP elevations induced by
cinaciguat, a so-called NO-GC activator, were not regulated by
flow (Fig. 2f). The differential effects of NO, NO-GC stimulators
and NO-GC activators on mechanosensitive cGMP signals are
likely related to their different binding sites on NO-GC and
modes of action. In contrast to NO and NO-GC stimulators,
NO-GC activators activate the enzyme even if it has been oxi-
dized or rendered heme-deficient7,30. Inhibition of cGMP efflux
with MK-571 did not affect flow-dependent cGMP increases in
the presence of NO (Fig. 2g). Together, these data suggested that
cGMP synthesis by NO-GC, but not cGMP degradation or efflux,
is the major shear-sensitive component of cGMP signaling in
platelets.
We also asked whether similar mechanosensitive cGMP
pathways might exist in other cell types exposed to physical
forces such as vascular smooth muscle cells (VSMCs) that are
naturally exposed to wall stress and stretch. Primary VSMCs
isolated from mouse aorta express several types of guanylyl
cyclases22. When we studied these VSMCs in flow chamber
experiments similar to those performed with platelets, we also
observed shear-sensitive cGMP transients in the presence of
NO, but not in the presence of CNP, which activates a
different type of guanylyl cyclase, GC-B (Supplementary Fig. 6a).
Considering that PDE5 inhibition augments both NO-induced22
and CNP-induced cGMP pools in VSMCs (Supplementary
Fig. 6b), but only the NO-induced cGMP pool was sensitive to
flow, it is likely that, similar to platelets, NO-GC but not PDE
activity, is the major mechanosensitive component shaping
cGMP signals in VSMCs. Indeed, we detected high amounts of
the NO-GC β1 subunit as well as cGKI associated with the
Fig. 1 A flow/shear-dependent NO-cGMP-cGKI cascade inhibits platelet thrombus formation ex vivo. Thrombi were formed ex vivo by perfusion of mouse
blood through a flow chamber over a collagen-coated surface at a shear rate of 500 s−1. a Thrombus formation by DiOC6-labeled platelets from control
mice (SM22+/Iβ; cGKI+/L−) or SM-Iβ rescue mice lacking cGKI in platelets (SM22+/Iβ; cGKIL−/L−) in the absence (left) or presence (right) of 1 μM DEA/
NO. Data are shown as mean ± SEM (n= 3). Scale bars, 50 μm. b FRET/cGMP imaging in cGi500-expressing platelet thrombi superfused with 100 nM
DEA/NO at a shear rate of 500 s−1. Thrombi were subjected to different shear conditions by switching the buffer flow off and on. Data are shown as mean
± SEM (n= 11 thrombi from one representative experiment out of 10 independent experiments). The cGMP concentration scale (upper right) is derived
from in-cell calibration of VSMCs25. c Western blot detection of VASP phosphorylation (p-VASP) in platelets exposed to buffer without (−) or with (+)
100 nM DEA/NO for 3 min under static or flow (500 s−1) conditions. The ratio of p-VASP/VASP was determined in three experiments; GAPDH was used
as loading control. d FRET/cGMP imaging in cGi500-expressing thrombi superfused with 50 nM DEA/NO at various shear rates (s−1). Data are shown as
mean ± SEM (n= 8 thrombi from one representative experiment out of three independent experiments). e, f Platelet thrombi from e sensor control
mice (cGi500-L2fl/fl; Pf4-Cretg/+; NO-GC β1+/fl) or f sensor mice with platelet-specific NO-GC β1 deficiency (cGi500-L2fl/fl; Pf4-Cretg/+; NO-GC β1fl/fl)
were exposed to flow (500 s−1) on/off conditions in the absence or presence of 100 nM DEA/NO. Data are shown as mean ± SEM (n= 10 thrombi).
Representative data from one of three independent experiments are shown. The significance level of P values is indicated by asterisks (*P < 0.05;
**P < 0.01; n.s., not significant; Student’s t-test)
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platelet membrane fraction (Fig. 2h). These findings are
consistent with the notion that NO-GC can be associated with
the plasma membrane in a state of enhanced NO sensitivity31. To
test if NO-GC activity is regulated by known mechanotransdu-
cers, we performed FRET/cGMP imaging in the presence of Pyr3
(a selective TRPC3 blocker), GsMTx4 (a nonselective blocker of
TRPC1, TRPC6, Piezo1, and stretch-activated cation channels),
or a β3 integrin-blocking antibody. However, none of these
compounds affected the flow-regulated cGMP signals in the
presence of NO (Supplementary Fig. 7). We suggest that NO-GC,
cGKI and other yet unidentified proteins form a signaling
complex at the plasma membrane, which converts mechanical
force into biochemical signals in platelets, VSMCs, and probably
many other cell types.
Shear-dependent cGMP signals lower intracellular Ca2+. To
address the molecular and functional consequences of shear-
regulated cGMP signaling, we monitored intrathrombus cGMP
and Ca2+ concentrations simultaneously in flow chamber
experiments. In the presence of NO, initiation of flow induced an
increase of cGMP and a decrease of the intracellular Ca2+ con-
centration, while cessation of flow resulted in inverse changes of
cGMP and Ca2+ (Fig. 2i). cGMP changes preceded Ca2+ changes
in each case (Fig. 2j). This finding, together with the fact that
measurements were performed in EGTA-containing imaging
buffer, indicated that mechanosensitive cGMP signals do not
require extracellular Ca2+ and that activation of shear-dependent
cGMP signaling lowers the intracellular Ca2+ concentration,








































































































Fig. 2 NO-GC activity is regulated by fluid shear stress and lowers the intracellular Ca2+ concentration. FRET/cGMP imaging of cGi500-expressing platelet
thrombi formed on collagen was performed under flow on (500 s−1) and off (0 s−1) conditions. a–c Thrombi were exposed to a DEA/NO (100 nM),
b SPER/NO (500 nM), or c DETA/NO (10 μM). At the end of each experiment, 20 μM ODQ was applied in the presence of the respective NO donor
and continuous flow. d–f Thrombi were superfused with the NO-GC stimulators d BAY 41-2272 (5 µM) or e riociguat (5 µM), or f with the NO-GC
activator cinaciguat (100 nM). g DEA/NO (100 nM)-induced cGMP signals in the presence of the MRP4 inhibitor, MK-571 (1 µM). Data are shown as
mean ± SEM (n= 18 thrombi in a, b, g; n = 10 thrombi in c, d; n = 15 thrombi in e, f). hWestern blot analysis of NO-GC β1, cGKI, and PECAM-1 in cytosolic
and membrane fractions of mouse platelets. Data are shown as mean ± SEM (n= 4). i Simultaneous imaging of cGMP (green trace) and Ca2+ (red trace)
in the presence and absence of flow and 100 nM DEA/NO. These measurements were performed in the presence of 0.2 mM EGTA. Data are shown as
mean ± SEM (n= 25 thrombi). j Traces between time points t1 and t2 of i are shown with inverted Ca2+ traces to facilitate analysis of the chronological
order of changes in cGMP and Ca2+. Results are representative of three independent experiments
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and phosphorylation of IRAG32. In line with this mechanism,
flow-dependent regulation of Ca2+ in the presence of NO was
abolished in cGKI-deficient mouse platelets (Supplementary
Fig. 8a, b). Moreover, the mechanosensitive NO-cGMP-Ca2+
pathway also exists in human platelets (Supplementary Fig. 8c).
Thus, in the presence of NO, fluid shear stress increases intra-
platelet cGMP resulting in suppression of Ca2+ signals and
inhibition of platelet activity, presumably via inhibition of ligand-
integrin interaction. The mechanosensitive crosstalk of cGMP
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the NO-cGMP-cGKI cascade under flow ex vivo (Fig. 1a; Sup-
plementary Fig. 1).
Platelet cGMP changes during thrombus growth in vivo. To
demonstrate that the shear stress-dependent NO-cGMP pathway
in platelets exists in vivo and inhibits thrombosis in the presence
of blood flow, we analyzed cGMP signals and thrombus growth
by intravital FRET microscopy in platelet-specific cGMP sensor
mice. Thrombus formation is a highly dynamic process with
cycles of platelet aggregation and disaggregation, resulting in
sequential increases and decreases of thrombus size and shear
rates acting on the platelets in the thrombus until the thrombus
has stabilized3,5,19. We first performed mechanical injury of
arterioles of the cremaster muscle with a micropipette and imaged
the developing thrombi using an epifluorescence microscope.
YFP fluorescence was detected selectively in thrombi indicating
platelet-specific expression of the cGi500 sensor in our mouse
model (Supplementary Fig. 9a). Superfusion of the cremaster
tissue with the NO-releasing drug sodium nitroprusside (SNP)
evoked robust FRET/cGMP signals in a concentration-dependent
manner (Supplementary Fig. 9b). After this proof-of-principle
experiment, we switched to confocal spinning disk FRET
microscopy that enables precise mapping of cGMP signals to
selected thrombus regions. Thrombus formation was induced by
mechanical injury, and after the thrombus stabilized, DEA/NO
was applied. Again, administration of an NO donor in the pre-
sence of blood flow induced strong increases of the FRET/cGMP
signals, which were validated by the fact that individual CFP and
YFP traces split into opposite directions (Fig. 3a–c). Importantly,
cGMP signals were also observed in growing thrombi in the
absence of exogenous NO, and these cGMP signals were stronger
in the periphery of the thrombus than in its core region
(Fig. 3d–f) (Supplementary Movie 2). The latter finding is con-
sistent with shear-sensitized NO-GC in platelets at the thrombus
periphery exposed to flow. In addition, limited diffusion of
endogenous NO into the thrombus core may also contribute to
the cGMP gradient from the periphery to the core region.
Interestingly, the magnitude of the cGMP signals correlated well
with the area of the developing thrombus (Fig. 3f). These results
indicated that an endogenous NO-cGMP system is active in
platelet thrombi exposed to shear stress in vivo.
Our findings are consistent with a model in which thrombus
growth leads to increased exposure of aggregated platelets to
shear stress19, which in turn promotes shear-dependent cGMP
signaling and inhibition of thrombus growth until it has
stabilized. To provide further support for this hypothesis, we
used a laser-induced thrombosis model33, which allows for higher
n-numbers required for statistical evaluation of data. As in the
mechanical injury model, FRET/cGMP imaging of growing
thrombi in the absence of exogenous NO showed dynamic
changes of the intraplatelet cGMP concentration that paralleled
thrombus growth, with the highest cGMP levels observed at the
shear-exposed periphery of the thrombus (Fig. 3g–i). Quantitative
analysis of FRET/cGMP signals demonstrated a significantly
higher cGMP concentration in the thrombus periphery versus its
core region in control mice (Fig. 3j). These FRET/cGMP changes
were not observed in cGMP sensor mice with a platelet-specific
NO-GC deletion (Fig. 3j, k), thus, confirming that the FRET
changes recorded by intravital microscopy in growing thrombi of
control mice reflected dynamic cGMP signals that depend on the
presence of NO-GC in platelets.
Shear-dependent cGMP facilitates thrombus dissolution. To
study the functional relevance of shear-dependent NO-cGMP
signaling for thrombosis in vivo, we compared profiles of
thrombus growth over time in control and platelet-specific
NO-GC knockout mice. After laser-induced injury of cremaster
arterioles, we observed striking differences in thrombus growth
profiles in the presence and absence of platelet NO-GC (Fig. 4a,
b) (Supplementary Movie 3 and Supplementary Movie 4). While
the time to maximal thrombus size and maximal thrombus size
was not significantly affected by the genotype, the time required
for subsequent thrombus dissolution from peak to 50% thrombus
area was significantly increased in the absence of platelet NO-GC
(Fig. 4b–e). Overall, deletion of NO-GC in platelets led to
increased thrombosis over time (Fig. 4f). In control mice, stabi-
lized thrombi at the end of the experiment were less elongated
and significantly smaller than in NO-GC knockout mice (Fig. 4a,
b, g). These results indicated that NO-cGMP signaling in platelets
in vivo facilitates thrombus stabilization.
Discussion
Proper platelet function requires precise temporal and spatial
regulation of platelet activation and inhibition. While our study
did not specifically examine the role of cGMP during initial
phases of platelet activation, we found that NO-induced cGMP
generation in already pre-activated platelets is dramatically
potentiated by shear stress and results in platelet inhibition at
later stages of thrombus formation. Intravital studies performed
in the mouse microcirculation showed that thrombi formed after
vascular injury develop a characteristic architecture with a core of
fully activated, densely packed platelets that is overlaid with a
shell of less activated platelets34,35. Interestingly, a recent study
showed that during the propagation phase, cAMP-dependent
protein kinase activity was increased in platelets detaching from
the downstream side of the aggregate, suggesting that high
activity of cAMP-dependent protein kinase is associated with
thrombus resolution36. Considering the similarities between
Fig. 3 Thrombus growth is associated with dynamic changes of intraplatelet cGMP in vivo. Platelet cGMP (black traces) and thrombus growth (red traces)
were visualized by intravital spinning disk FRET microscopy of cremaster arterioles. Vessel walls are outlined by broken white lines, and white arrows
indicate the direction of blood flow. a–f cGMP imaging in thrombi formed in platelet-specific sensor mice (cGi500-L2fl/fl; Pf4-Cretg/+) after mechanical
vessel injury. a Sensor fluorescence confirms its specific expression in platelets. b, c cGMP concentration shown by CFP/YFP emission ratio (R= F480/
F535) in a stable thrombus before (t1) and after (t2) application of 10 μM DEA/NO. The cGMP level in the entire thrombus is shown in c. The signals at
time point t1 and t2 correspond to the images shown in b. d–f Endogenous cGMP and thrombus area during mechanical injury-induced thrombosis. Note
that no exogenous NO was applied. The cGMP level in the periphery of the thrombus is shown in f. The signals at time point t1 and t2 correspond to the
images shown in e. g–k Endogenous cGMP and thrombus area during laser-induced thrombus formation. Representative results obtained with sensor
control mice (cGi500-L2fl/fl; Pf4-Cretg/+; NO-GC β1+/fl) (g–i) or sensor mice with platelet-specific NO-GC β1 deficiency (cGi500-L2fl/fl; Pf4-Cretg/+; NO-GC
β1fl/fl) (k) are shown. Note that no exogenous NO was applied. The signals at time point t1 and t2 (i) correspond to the images shown in h. j Evaluation of
maximal FRET signal changes in the entire thrombus as well as in its core and periphery in control (Ctrl) and platelet-specific NO-GC β1 knockout (KO)
mice. Data points represent individual thrombi (n= 6 and 10 respectively, mean ± SEM, *P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA). Color
calibration bars in b, e, h indicate relative cGMP concentrations. Scale bars in a, d, g 10 μm
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cAMP and cGMP signaling, this finding is consistent with our
data indicating that high cGMP concentrations in shear-exposed
platelets at the thrombus periphery limit thrombosis primarily
through facilitation of thrombus dissolution.
Taken together, our data support a concept of shear-dependent
inhibition of thrombosis via the NO-cGMP-cGKI cascade (Sup-
plementary Fig. 10) and also provide a mechanistic explanation
for the finding that human gene mutations leading to impaired
cGMP generation in platelets are associated with an increased risk
of myocardial infarction10. Platelets that are recruited to the
periphery of a growing thrombus are exposed to increasing shear
stress as the thrombus becomes bigger. With increased thrombus
size, shear-dependent cGMP synthesis in platelets at the
periphery of a thrombus increases resulting in activation of cGKI
and suppression of Ca2+-dependent platelet activity. NO that
activates shear-sensitized NO-GC in platelets is likely generated
by the vascular endothelium, presumably also in a shear stress-
dependent manner37–39. Thus, NO generation in endothelial cells
as well as cGMP synthesis in platelets appears to require shear
stress. In this way, the mechanosensitive NO-cGMP cascade
provides a negative feedback control of shear stress-induced
platelet activation. It acts as an auto-regulatory brake to achieve a
balance between activating and inhibiting mechanisms until a
thrombus is eventually stabilized. The cGMP brake mechanism is
well designed to enable an optimal hemostatic response. It should


































































































































































Fig. 4 Increased thrombosis and thrombus dissolution time in platelet-specific NO-GC knockout mice. a–g Laser-induced thrombosis in cremaster
arterioles of control mice (Ctrl) (cGi500-L2fl/fl; Pf4-Cretg/+; NO-GC β1+/fl) and platelet-specific NO-GC β1 knockout mice (NO-GC KO) (cGi500-L2fl/fl;
Pf4-Cretg/+; NO-GC β1fl/fl). a Representative fluorescence (YFP) images of platelet thrombi at indicated time points after laser injury. Vessel walls are
outlined by broken white lines, and white arrows indicate the direction of blood flow. Scale bars, 10 μm. b Profile of thrombus growth shown in a depicted
as thrombus area over time in Ctrl (black) and NO-GC KO (red) mice. Various aspects of thrombus formation were evaluated: c Time to maximum
thrombus size; d Maximal thrombus size; e Thrombus half dissolution time, i.e. the time required after peak maximum to decline to 50%; f Area under
curve, which reflects integrated thrombus size over time; g Size of stabilized thrombi at the end of the experiment (300 s). Data are shown as mean ± SEM;
n= 31 and 37 thrombi in b–f generated in 10 Ctrl and 7 NO-GC KO mice, respectively; n= 27 and 33 thrombi in g generated in 10 Ctrl and 7 NO-GC KO
mice, respectively. h Tail bleeding time (mean ± SEM) in control mice (SM22+/Iβ; cGKI+/L−) and SM-Iβ rescue mice lacking cGKI in platelets (SM22+/Iβ;
cGKIL−/L−) (n= 13 and 11 mice, respectively). Statistical significance was analyzed in c–g using Student’s t-test (or Welch t-test for samples with non-equal
variances) and in h using Mann–Whitney U test. *P < 0.05; n.s., not significant
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under high shear conditions, which are also known to lead to
strong platelet activation, while it should not promote bleeding
from injured vessels under low shear. Indeed, in a tail vein
bleeding assay, in which platelets are exposed to shear rates ten
times lower than in arteries40, the bleeding time of mutant mice
lacking cGKI in platelets was not significantly different from
controls (Fig. 4h). Thus, drugs that activate platelet NO-GC in a
shear-sensitive manner, such as NO donors or the clinically used
NO-GC stimulator riociguat (Fig. 2a–e), could be anti-throm-
botics, which, unlike currently used anti-thrombotic therapies,
inhibit arterial thrombosis without the life-threatening risk of
bleeding. It is tempting to speculate that the mechanosensitive
NO-cGMP-cGKI cascade in platelets provides a mechanism for
the beneficial effects of NO donors in treating ischemic heart
disease.
Methods
Animals and reagents. R26-CAG-cGi500(L1) (cGi500-L1) mice express the
cGMP sensor cGi500 globally, and R26-CAG-cGi500(L2) (cGi500-L2) mice
express cGi500 after crossing to appropriate Cre mice in a cell type-specific
manner22. cGMP sensor mice on a mixed 129Sv/C57BL6N genetic background
were back-crossed for ten generations to C57BL/6N mice. cGi500-L2 mice were
crossed to Pf4-Cre mice23 to obtain megakaryocyte/platelet-specific cGi500 mice
(cGi500-L2fl/fl; Pf4-Cretg/+). Mice with platelet-specific cGi500 expression and
platelet-specific NO-GC deletion (cGi500-L2fl/fl; Pf4-Cretg/+; NO-GC β1fl/fl) were
generated by crossing conditional NO-GC β1 knockout mice26 with cGi500-L2 and
Pf4-Cre mice. cGKIβ smooth muscle rescue animals (SM-Iβ; genotype: SM22+/Iβ;
cGKIL−/L−)21, which lack cGKI expression in platelets, were on a C57BL/6N
genetic background. Animal experiments were performed in accordance with all
relevant ethical regulations and had been approved by the Regierungspräsidium
Tübingen (IB 2/15). Atrial natriuretic peptide (ANP), C-type natriuretic peptide
(CNP), Pyr3, and fibrinogen was purchased from Sigma Aldrich; fibrillar type I
collagen from Nycomed; DEA/NO, SPER/NO, DETA/NO, SNP, and ODQ from
Axxora; MK-571, BAY 41-2272, BAY 60-7550, milrinone, tadalafil, and 3,3′-
dihexyloxacarbocyanine iodide (DiOC6) from Santa Cruz; riociguat from Med-
chem Express; cinaciguat from Cayman Chemical; GsMTx4 from Alomone labs;
anti-β3 integrin antibody from Biolegend (1:100, 104309) and Fura-2/AM from
Calbiochem.
Thrombus formation in a flow chamber and immunostaining. Rectangular
coverslips (24 × 60 mm) for flow assays were coated with 200 μg/mL fibrillar type I
collagen over night at 4 °C and then blocked with 1% BSA solution for at least
30 min at room temperature. 12- to 20-week-old mice were anesthetized without
reawakening and 700 μL blood was collected from the retro-orbital plexus into a
falcon tube containing 300 μL of heparin in PBS (20 U/mL). Blood was mixed with
platelet Tyrode buffer (in mM: 10 HEPES, 137 NaCl, 12 NaHCO3, 2.7 KCl, 5.5 D-
glucose, pH 7.4; supplemented with 0.1% BSA) in a ratio of 2:1. Using a syringe
pump (B-Braun), this mixture was perfused through a flow chamber (μ-Slide I0.1
or μ-Slide I0.2, ibidi) mounted with a collagen-coated coverslip at a shear rate of
500 s−1 (corresponding to a shear stress of 5 dyn/cm2) at room temperature. The
shear rate depends on the flow rate and geometry/height of the flow chamber and
was calculated according to formulas given by the manufacturer (ibidi). Human
blood was drawn from healthy volunteers into tubes containing citrate phosphate
dextrose-adenine-1 (Sarstedt) and used for thrombus formation in a flow chamber
as described for murine blood. We have complied with all relevant ethical reg-
ulations and all human participants gave written informed consent. The study was
approved by the institutional ethics committee (Ethik-Kommission an der Medi-
zinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum
Tübingen) (474/2014BO2). Before perfusion through the flow chamber, human
blood or blood from mice not expressing the cGi500 sensor was fluorescently
labeled by pre-incubation with 0.5 μg/mL DiOC6 for 3 min at room temperature.
For immunofluorescence staining, platelet thrombi were fixed for 10 min with 4%
formalin, blocked with 5% normal goat serum for 1 h, and then incubated with
anti-mouse/rat CD62P (P-selectin) antibody (2 μg/mL; 1:250, Biolegend, 148301)
for 1 h. After washing with PBS, cells were incubated with Alexa Fluor
488–conjugated secondary antibody diluted in PBS (1:500, Invitrogen, 51663A) at
room temperature for 1 h and embedded in Immu-Mount (Thermo Scientific).
Primary vascular smooth muscle cells (VSMCs). Primary VSMCs were isolated
from aortae of cGi500-L1 mice22. Single cells were obtained by incubation of aortic
tissue for 45 min at 37 °C with papain (0.7 mg/mL) followed by 10–15 min with
collagenase (1 mg/mL) and hyaluronidase (1 mg/mL), and then plated on rectan-
gular glass coverslips. Cells were grown in culture medium (DMEM with 4.5 g/L
glucose, 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin)
at 37 °C and 6% CO2 for 5–7 days and serum-starved for 24 h before mounting into
an ibidi flow chamber for microscopic analysis and FRET/cGMP imaging.
FRET/cGMP imaging in platelets and VSMCs under flow ex vivo. FRET/cGMP
imaging of cells ex vivo was performed in flow chambers (ibidi) using an epi-
fluorescence setup (Supplementary Fig. 3a) based on an inverted Axiovert 200
microscope (Zeiss) equipped with EC Plan NeoFluar 10×/0.3, LD Plan NeoFluar
20×/0.4 air, and Plan NeoFluar 40×/1.3 oil objectives and optional 1.6× Optovar
magnification (Zeiss). The imaging setup contains a light source with excitation
filter switching device (Oligochrome, TILL Photonics GmbH), a DualView beam
splitter with 516 nm dichroic mirror and CFP and YFP emission filters (480/30 nm
and 535/40 nm) (Photometrics), and a CCD digital camera (Retiga 2000R,
QImaging)22. Images were acquired at 0.2 Hz or 1 Hz at room temperature.
Adherent cells were exposed to flow at a shear rate of 500 s−1 using a syringe pump
(B-Braun). Platelet thrombi and VSMCs were superfused at room temperature with
platelet Tyrode buffer and imaging buffer (in mM: 5 HEPES, 140 NaCl, 5 KCl,
1.2 MgCl2, 2.5 CaCl2, 5 D-glucose, pH 7.4), respectively. Drugs were applied via two
sample loops connected in series and controlled by injection valves (Pharmacia
V-7, GE Healthcare).
Simultaneous FRET/cGMP and Ca2+ imaging. Blood from 12- to 20-week-old
cGi500-L1 mice was perfused through a flow chamber (ibidi) for thrombus for-
mation on a collagen-coated surface as described above. Platelet thrombi were
loaded with 2.5 µM Fura-2/AM in platelet Tyrode buffer for 45 min at room
temperature. A combination of filter and mirror sets was used to allow simulta-
neous recording of Fura-2/Ca2+ and FRET/cGMP signals at room temperature. An
Oligochrome light source (TILL Photonics) was used to alternately excite Fura-2 at
340/26 nm and 387/11 nm, and the CFP of cGi500 at 445/20 nm. CFP and YFP
emission were recorded with a CCD camera (Retiga2000R, Photometrics). Fluor-
escence channels were separated using a 470 nm dichroic mirror together with a
beam splitter (DualView DV2; Photometrics) equipped with a 516 nm dichroic
mirror and CFP and YFP emission filters (480/30 nm and 535/40 nm, respectively).
In each acquisition cycle, cells were sequentially excited at 340/26 nm, 387/11 nm
and 445/20 nm and emitted light was recorded at 480/30 nm and 535/40 nm.
Images were acquired at 0.2 or 1 Hz. For Ca2+ imaging of Fura-2 loaded mouse or
human platelets not expressing the cGMP sensor, the same setup was used, but
without the beam splitter. Samples were sequentially excited at 340/26 nm and
387/11 nm, and Fura-2 emission was recorded using a 410 nm dichroic mirror and
440LP filter41.
cGMP ELISA of platelet suspensions. Murine blood was drawn from the retro-
orbital plexus of 12- to 20-week-old mice under anesthesia without reawakening
into 7xACD buffer (in mM: 85 sodium citrate, 72.9 citric acid, 110 D-glucose). To
obtain platelet-rich plasma, blood was centrifuged at 250×g for 2 min at room
temperature. Then, the supernatant was centrifuged at 2000×g for 2 min. Pelleted
cells were washed in platelet wash buffer (in mM: 4.3 K2HPO4, 4.3 Na2HPO4, 24.3
NaH2PO4, 113 NaCl, 5.5 D-glucose, pH 6.5) supplemented with 0.1% BSA and
resuspended at a density of 6.4 × 108 mL−1 in platelet Tyrode buffer supplemented
with 0.1% BSA. Tubes containing suspensions of washed platelets in Tyrode buffer
(5 × 107 platelets per sample) were placed at room temperature in racks and
incubated with 50 nM DEA/NO for 15 s without vortexing (static condition) or on
a vortex shaker (Barnstead Thermolyne Maxi Mix II Vortex Shaker, set to full
speed). Control platelets were allowed to rest without DEA/NO and vortex treat-
ment. Then, ice-cold ethanol was added to a final concentration of 66% ethanol.
Tubes were put on ice for 15 min and then centrifuged at 18,000×g for 10 min at
4 °C. Supernatants were dried at 90 °C and the cGMP content was determined
using an enzyme immunoassay kit (Cyclic GMP EIA Kit, Cayman Chemical)
according to the manufacturer’s protocol.
Western blot analysis. For the stimulation of platelets under static conditions,
platelets were prepared from murine blood as described above for cGMP ELISA.
Platelet Tyrode buffer or 100 nM DEA/NO was added to isolated platelets (2 × 108
mL−1) in platelet Tyrode buffer in a test tube and incubated for 3 min at room
temperature. Then, platelets were spun down at 2000 × g for 1 min, the supernatant
was removed, SDS-containing lysis buffer was added, and the lysate heated to 95 °C
for 5 min. For the stimulation of platelets under flow, platelet thrombi in a flow
chamber were subjected to shear at 500 s−1 in the absence and presence of 100 nM
DEA/NO for 3 min at room temperature. Then, platelets were immediately lysed in
SDS-containing lysis buffer and heated to 95 °C for 5 min. Lysates were used for
detection of VASP phosphorylation by western blotting41. Primary antibodies were
against VASP/pVASP (rabbit, 1:1000; Cell Signaling, 9A2, 3132), or GAPDH
(rabbit, 1:5000; Cell Signaling, 14C10, 2118). The secondary antibody was goat
anti-rabbit horseradish peroxidase (HRP)-conjugated IgG (1:5000; Cell Signaling,
7074). For detection of protein localization, cytosolic and membrane fractions were
prepared from isolated murine platelets subjected to hypotonic shock31. The pla-
telet suspension in platelet Tyrode buffer was centrifuged at 20,000 × g for 1 min
at 4 °C and the resulting pellet was lysed in ice-cold hypotonic buffer (in mM:
10 EDTA, 10 NaH2PO4, 1 PMSF, pH 7.6). Lysates were then centrifuged at
100,000 × g for 1 h at 4 °C. The supernatant (cytosolic fraction) was collected into a
new tube. The pellet (membrane fraction) was washed once with hypotonic buffer,
centrifuged at 100,000 × g for 1 h at 4 °C, and then resuspended in hypotonic
buffer, so that the final volume of the membrane fraction was equal to the volume
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of the cytosolic fraction. After adding SDS-containing lysis buffer, samples were
denatured at 95 °C for 10 min. Equal volumes of cytosolic and membrane fractions
were analyzed by western blotting using antibodies against PECAM-1 (goat, 1:500;
Santa Cruz, sc-1506), cGKI (rabbit, 1:5000)42 and NO-GC β1 (rabbit, 1:10,000;
raised against a protein comprising the 350 N-terminal amino acids of NO-GC β1
fused to glutathione-S-transferase). Uncropped images of all representative blots
shown in the manuscript are provided in the supplementary information (Sup-
plementary Fig. 11).
Thrombosis models and intravital FRET/cGMP imaging in vivo. The mouse
cremaster muscle was prepared for intravital microscopy43. Male cGi500-
expressing mice were anesthetized by intraperitoneal injection of fentanyl (0.05 mg
kg−1), midazolam (5 mg kg−1), and medetomidin (0.5 mg kg−1). Then, the cre-
master muscle was exteriorized, cleaned of connective tissue, and spread flat on the
pedestal of a custom-built imaging platform. Body temperature was maintained at
37 °C by convective heat throughout the experiment. The cremaster was con-
tinuously superfused with saline buffer (in mM: 118.4 NaCl, 20 NaHCO3, 3.8 KCl,
2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4) warmed to 35 °C and bubbled with 95%N2/5%
CO2. SNP or DEA/NO was diluted 1:100 into the superfusion solution using a
roller pump to achieve a final concentration of 3–100 μM or 10 µM on the tissue,
respectively. Arterioles with a diameter of 30–60 µm and unperturbed blood flow
were selected for study. To induce thrombosis by mechanical injury, the skeletal
muscle was carefully removed from the selected arteriole to facilitate subsequent
injury of the vessel wall by puncture with a micromanipulator-controlled glass
micropipette (1-µm tip). Alternatively, a laser-induced thrombosis model was used.
Here, thrombus formation was initiated by injuring an arteriole of the intact cre-
master muscle with an ablation laser (teem photonics; wavelength 532 nm; energy
per pulse >3 μJ; pulse width <0.5 ns; peak power >6 kW) on a spinning disk
microscope. Growing thrombi induced by mechanical injury were imaged with an
upright epifluorescence microscope (Axioskop 2 FS, Zeiss) equipped with a water
immersion objective (Achroplan 40×/0.75W), a polychromatic light source
(Polychrome V, TILL Photonics) set to 420 nm, and an EM-CCD camera
(QuantEM 512, Photometrics), or with a spinning disk microscope. Laser-induced
thrombosis was monitored with the spinning disk microscope. The spinning disk
setup comprised an upright microscope (Axio Examiner Z1, Zeiss), a Yokogawa
CSU-X1 spinning disk confocal scanner, diode lasers of 445 nm, 488 nm and 561
nm, water-immersion objectives (W N-ACHROMAT 10x/0.3, W Plan-
APOCHROMAT 20×/1.0 DIC (UV) VIS-IR, W Plan-APOCHROMAT 40×/1.0
DIC VIS-IR; all from Zeiss), an oil-immersion objective (Plan-APOCHROMAT
63×/1.4 Oil DIC; Zeiss) and an air objective (EC Plan-NEOFLUAR 2.5×/0.085;
Zeiss), a DualView DV2 beam splitter (Photometrics; equipped with 470/24 nm
CFP emission filter, 505 nm dichroic mirror, and 535/30 nm YFP emission filter),
an EM-CCD camera (QuantEM 512, Photometrics), and a CCD camera (Spot
Pursuit, Diagnostic Instruments). A pE-2 LED system (CoolLED) was used for
epifluorescence illumination at 400 nm, 450 nm, 500 nm, and 561 nm. Simulta-
neous recording of CFP and YFP emission was performed using the EM-CCD
camera in combination with the beam splitter. The system was controlled by
VisiView software (Visitron Systems). Images were acquired at a rate of 1 Hz with
300 ms exposure.
Evaluation of imaging data and thrombus growth. Offline image analysis was
done using arivis Browser 2D software (Arivis) or Fiji44. For further data evalua-
tion, Microsoft Excel (Microsoft), Graphpad Prism 7 and Origin Pro 2016 (Ori-
ginLab) were used. For epifluorescence-based FRET/cGMP imaging, the mean
intensity from selected regions of interest of the CFP and YFP channel images was
corrected for background fluorescence and is referred to as F480 and F535,
respectively. The cGMP-representing fluorescence ratio R was calculated as F480/
F535. ΔF480/F480, ΔF535/F535, and ΔR/R traces were generated by normalization
to the respective baseline. Since the emission spectrum of Fura-2 overlaps with
emission of CFP and YFP, emission of Fura-2 can be collected with the same filters
used for the CFP/YFP FRET pair. The images from the 535 nm channel excited at
340 nm and 380 nm were used to analyze Fura-2 emission, processed analogously
to F480 and F535 and are referred to as F340 and F380, respectively. To estimate
peak areas of ΔR/R traces, the Peak Analyzer Module of Origin was used. Traces
were corrected for baseline drifts by subtracting a linear baseline, and peak borders
were manually defined. To evaluate FRET/cGMP signals in a dynamic thrombus
recorded during intravital imaging, masks were applied to select different regions of
interest, i.e. the whole thrombus, its core, or its periphery. Image segmentation was
applied based on thrombus brightness using a similar approach as described for the
analysis of FRET/cGMP signals in the vessel wall43. Measurements with a signal-to-
noise ratio below 2.5 were excluded from analysis. The sum of CFP and YFP
fluorescence intensities was used to define a dynamic binary mask. Gaussian blur
filtering (sigma radius= 2 pixels) was applied to the sum image of CFP and YFP
when generating the binary mask. An intensity threshold was manually set to
segment the whole thrombus from the background. To further segment the core
and periphery of the thrombus, the original thresholded mask for the whole
thrombus was divided into two portions, i.e. the mask was further eroded by a user-
defined distance (defined as ~20% higher than original threshold intensity). The
portion remaining after erosion was taken as thrombus core. The portion removed
by erosion was taken as the thrombus periphery. The dynamic masks were
multiplied with the original CFP and YFP images to generate new CFP and YFP
time lapse images, respectively. A region of interest was selected to cover the whole
thrombus during the time lapse recording. Background was selected in a region
without thrombus in the original CFP or YFP image without mask applied.
Background corrected F480 and F535 signals were used for FRET evaluation. The
profile of thrombus growth was analyzed by measuring thrombus area as a function
of time. The area under the curve reflecting thrombosis over time was determined
by analyzing peak area of the thrombus growth profile using the Peak Analyzer
Module of Origin. In addition, thrombus formation was characterized by the fol-
lowing parameters: time to maximal thrombus size, the magnitude of maximal
thrombus size, thrombus half dissolution time, defined as the time from maximal
thrombus size to 50% of maximal thrombus size, and size of stabilized thrombus at
the end of the experiment.
Tail bleeding assay. Litter-matched control and mutant mice were anesthetized
without reawakening by intraperitoneal injection of fentanyl (0.05 mg kg−1),
midazolam (5 mg kg−1) and medetomidin (0.5 mg kg−1). The tail tip (5 mm) was
cut off with a scalpel. Blood drops were collected every 20 s on a filter paper
without touching the lesion until blood flow stopped. Bleeding exceeding 15 min
was stopped using tissue glue. After completion of the tail bleeding assay, blood was
drawn from the retro-orbital plexus of each anesthetized animal and platelet counts
were determined using an automated cell counter (Sysmex GmbH). Only mice with
a normal range of platelet counts (800–1300 × 106 mL−1) were included for ana-
lysis of the bleeding time.
Statistics. Data are expressed as mean ± SEM. Statistical differences between more
than two groups were analyzed by one-way ANOVA followed by Tukey’s multiple
comparison test. For parametric data, statistical significance was analyzed using
Student’s t-test (or Welch t-test for samples with non-equal variances) following
determination of normal distribution and equal variances. For non-parametric data
(bleeding time analysis), Mann–Whitney U test was applied. P values < 0.05 were
considered significant. The significance level of P values is indicated by asterisks
(*P < 0.05; **P < 0.01; ***P < 0.001; ns., not significant). All analyses were per-
formed with Origin software.
Data availability
The data that support the findings of this study are available from the corre-
sponding author upon reasonable request.
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